Loading organizations...
Based in Niel, Belgium, Etherna is a biotechnology company that develops nucleic acid-based medicines, focusing on mRNA and lipid nanoparticle technologies for therapeutics and vaccines. The organization operates through a partnership-driven business model, providing its pharmaceutical and biotech clients with discovery, development, and manufacturing services. These service offerings include access to customizable lipid nanoparticles, advanced RNA chemistry expertise, and scalable process technologies. Operating with a current workforce of more than 75 team members, the enterprise has secured €39 million in Series B2 funding to advance its proprietary platforms and manufacturing capabilities. The company's leadership and investor base feature prominent industry figures, including Chairman Marijn Dekkers, the former chief executive officer of Bayer AG and Thermo Fisher Scientific, alongside investor Kenneth Chien, a co-founder of Moderna. Currently led by CEO Bernard Sagaert, Etherna was founded in 2013.
Etherna has raised $77.3M across 2 funding rounds.
Etherna has raised $77.3M in total across 2 funding rounds.
Etherna has raised $77.3M in total across 2 funding rounds.
Etherna's investors include Marijn Dekkers, Kenneth Chien, Fund+, Grand Pharma, LSP, Omega Funds, PMV, BNP Paribas Fortis Private Equity, Boehringer Ingelheim Venture Fund, Grand Decade, Novalis LifeSciences, Yijing Capital.
Etherna has raised $77.3M across 2 funding rounds. Most recently, it raised $38.9M Series B in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 27, 2022 | $38.9M Series B | Marijn Dekkers | Kenneth Chien, Fund+, Grand Pharma, LSP, Omega Funds, PMV | Announced |
| Jun 16, 2020 | $38.4M Series B | — | BNP Paribas Fortis Private Equity, Boehringer Ingelheim Venture Fund, Fund+, Grand Decade, LSP, Novalis LifeSciences, Omega Funds, PMV, Yijing Capital | Announced |
